Buy Sagility; target of Rs 57: Motilal Oswal

Moneycontrol • 9 days ago

Original source

Key Investment Pillars

  • Sagility's revenue growth is driven by a combination of organic growth and acquisitions, with a focus on increasing the provider contribution to revenue.
  • The company has raised its FY27 adjusted EBITDA margin guidance to 25-26%, supported by operating efficiencies, favorable FX, and geographical mix.
  • Sagility's acquisition of Chirok adds clinical documentation improvement, medical coding, risk adjustment, and HEDIS quality capabilities, complementing its front-end patient access and back-end denials and accounts receivable services.
  • The company is progressing from individual AI use cases towards end-to-end agentic AI workflows, with solutions including Smart Tech Appeals Assist, Nurse Assist, and Claims Assist.

Thesis Validation Checklist

  • Revenue growth: Low- to mid-teens growth in FY27, driven by organic growth and acquisitions.
  • Margin expansion: Adjusted EBITDA margin to remain broadly within the 24-26% range over the medium term.
  • Provider contribution: Increase in provider contribution to revenue, with a dedicated sales team and Chirok's capabilities.
  • AI adoption: Progression from individual AI use cases to end-to-end agentic AI workflows, with solutions including Smart Tech Appeals Assist, Nurse Assist, and Claims Assist.